




10/531967
Rec'd PCT/PTO 20 APR 2005
TEPO 3711601



INVESTOR IN PEOPLE



The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 5 August 2003


BEST AVAILABLE COPY

1/77

Request for grant of a patent

(See the notes on the back of this form. You can get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP10 8QQ



432739P1

1. Your reference

2. Patent application number

(The Patent Office will fill in this part)

0224455.6

3. Full name, address and postcode of the
or of each applicant
(underline all surnames)

NOVARTIS AG
LICHTSTRASSE 35
4056 BASEL
SWITZERLAND

22 OCT 02 E757437-3 D00524
P01/7700 0.00-0224455.6


Patent ADP number (if you know it)

If the applicant is a corporate body,
give the country/state of its
incorporation

7125487005

4. Title of invention

Organic compounds



B.A. YORKE & CO.
CHARTERED PATENT AGENTS
COOMB HOUSE, 7 ST. JOHN'S ROAD
ISLEWORTH
MIDDLESEX TW7 6NH

1800001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application
number
(if you know it)

Date of filing
(day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier
application

Date of filing
(day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

(see note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 9

Claim(s) 2

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)


Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date



B.A. Yorke & Co.

21 October 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. E. Cheetham
020 8560 5847

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) Once you have filled in the form you must remember to sign and date it.
- e) For details of the fee and ways to pay please contact the Patent Office.

DUPLICATE


- 1 -

Organic Compounds

The invention relates to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide (hereinafter referred to as "Compound I") or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for the treatment of uveal melanoma, to the use of Compound I or a pharmaceutically acceptable salt thereof in the treatment of uveal melanoma, to a method of treating warm-blooded animals including mammals, especially humans, suffering from uveal melanoma by administering to a said animal in need of such treatment a dose effective against said disease of Compound I or a pharmaceutically acceptable salt thereof.

Uveal melanoma is the most common primary intraocular tumor in adults with an annual incidence of 6 cases per million. Uveal melanoma metastasizes preferentially to the liver, and the prognosis for affected patients is extremely poor. The average survival time in uveal melanoma is only 2-5 months after detected liver metastases. In contrast to improved survival rates in a variety of cancers where there is a continuing evolution toward early detection and management, the survival rate with uveal melanoma has changed little during the past few decades (Diener-West *et al.*, 1992, Arch. Ophthalmol. 110:245-50). Uveal melanoma is usually treated by enucleation or irradiation both leading to a poor prognosis of patients. Moreover, radiation therapy induces numerous complications such as neovascular glaucoma. Chemotherapy and/or immunotherapy has been used in the treatment of metastatic melanoma but the results have generally been disappointing, with a median survival time after treatment of 5 to 8 months (Pyrhonen S. 1998, Eur. J. Cancer 34, Suppl. 3:S27-30). There is a need for efficient and less traumatic treatments of uveal melanoma.

Compound I is 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide having the following formula



Compound I free base, its acceptable salts thereof and its preparation are disclosed in the European granted patent 0564409. Compound I free base corresponds to the active moiety.

The monomethanesulfonic acid addition salt of Compound I (hereinafter referred to as "Salt I") and a preferred crystal form thereof (the beta crystal form) are described in PCT patent application WO99/03854 published on January 28, 1999.

Surprisingly, it was found that Compound I is particularly useful for the treatment of uveal melanoma. Compound I promotes *in vitro* cell death on four uveal melanoma cell lines, possibly through the inhibition of c-kit phosphorylation.

The term "uveal melanoma" means any tumor deriving from the uvea. The uvea consists of the iris (the colored or pigmented part surrounds the pupil, the opening that controls the amount of light that enters the eyeball), the choroid (a thin, pigmented layer lining the eyeball that nourishes the retina and the front of the eye with blood), the ciliary body (contains the muscles inside the eye that change the shape of the lens so that the eye can focus on near or distant objects and cells that produce aqueous humor, fluid in the eye).

The invention thus relates to the use of a c-kit inhibitor or a pharmaceutically acceptable salt thereof as a drug against uveal melanoma. Most preferably, the invention relates in the use of Compound I or a pharmaceutically acceptable salt thereof as a drug against uveal melanoma.

The present invention further pertains to the use of Compound I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of uveal melanoma.

The pharmaceutical compositions according to the present invention can be prepared in a manner known per se and are those suitable for enteral, such as oral or rectal, and parenteral administration to warm-blooded animals, including man, comprising a therapeutically effective amount of at least one pharmacologically active ingredient, alone or in combination with one or more pharmaceutically acceptable carriers, especially suitable for enteral or parenteral application. The preferred route of administration of the dosage forms of the present invention is orally.

Hence, the invention also relates to a method of treating a warm-blooded animal having uveal melanoma comprising administering to said animal in need for such a treatment Compound I in a quantity which is therapeutically effective against uveal melanoma.

The invention relates to a method for administering to a human subject suffering from uveal melanoma an acid addition salt and preferably Salt I, the monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.

The person skilled in the pertinent art is fully enabled to select relevant test models to prove the beneficial effects mentioned herein on uveal melanoma. The pharmacological activity of such a compound may, for example, be demonstrated by means of the Examples described below, by *in vitro* tests and *in vivo* tests or in suitable clinical studies. Suitable clinical studies are, for example, open label non-randomized, dose escalation studies in patients with metastatic uveal melanoma. The efficacy of the treatment is determined in these studies, e.g., by evaluation of the tumor sizes every 4 weeks, with the control achieved on placebo.

The effective dosage of Compound I may vary depending on the particular compound or pharmaceutical composition employed, on the mode of administration, the type of the uveal melanoma being treated or its severity. The dosage regimen is selected in accordance with a variety of further factors including the renal and hepatic function of the patient. A physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of compounds required to prevent, counter or arrest the progress of the condition.

Depending on age, individual condition, mode of administration, and the clinical picture in question, effective doses, for example daily doses of Compound I or a pharmaceutically acceptable salt thereof corresponding to 100 to 1000 mg of the free base as active moiety, especially 800 mg, are administered to warm-blooded animals of about 70 kg body weight. Preferably, the warm-blooded animal is a human. For patients with an inadequate response to daily doses, dose escalation can be safely considered and patients may be treated as long as they benefit from treatment and in the absence of limiting toxicities.

The invention relates also to a method for administering to a human subject suffering from uveal melanoma, Compound I or a pharmaceutically acceptable salt thereof, which comprises

administering a pharmaceutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to the human subject once daily for a period exceeding 3 months. The invention relates especially to such method wherein a daily dose of 400 to 800 mg preferably 800 mg, of Compound I is administered to an adult.

Example 1: Dose response for the treatment of 4 uveal melanoma cell lines with Salt I after a 48 hours exposure.

Salt I anti-proliferative effects are determined by *in vitro* culture of four uveal melanoma cell lines in the presence of Salt I.

Cell culture: Four cell lines obtained from human primary uveal melanomas (OCM-1; OCM-3, 92-1 and mel 202) are used. They are kindly provided by Dr Martine Jager (Leiden University Medical Center, Leiden, The Netherlands).

Cell viability assay: Cell proliferation kit II is purchased from Roche Diagnostic GmbH (Mannheim, Germany). The test is based on a colorimetric change of the yellow tetrazolium salt XTT into orange formazan dye by the respiratory chain of viable cells (Roehm *et al.*, 1991, *J. Immunol. Assay*, 142:257-265).

Results

A) Dose response of Salt I on 9-21, OCM-1, mel 202 and OCM-3 cells

[Salt I] in μM			0	0.15	0.3	0.6	1.25	2.5	5	10
UM 92-1	1	24 h	100	97	98	95	97	93	83	70
		48 h	100	87	85	79	50	23	15	0
	2	24 h	100	107	91	102	97	102	75	83
		48 h	100	92	90	71	46	18	22	5
OCM-1	1	24 h	100	90	95	87	70	78	63	50
		48 h	100	98	62	40	24	15	27	23
	2	24 h	100	102	97	82	80	75	63	52
		48 h	100	73	59	37	34	32	23	29
mel 202	1	24 h	100	100	98	92	83	98	97	78
		48 h	100	24	23	19	15	13	23	21
	2	24 h	100	98	105	104	95	98	101	87

		48 h	100	5	14	17	22	11	15	7
OCM-3	1	24 h	100	100	100	100	97	95	85	87
		48 h	100	51	43	34	35	32	25	23
	2	24 h	100	110	97	105	102	87	83	98
		48 h	100	58	39	27	25	14	11	11

To examine the anti-proliferative effects of Salt I on the uveal melanoma cell lines, OCM-1, OCM-3, 92-1 and mel 202, cells are incubated with different concentrations of the drug for 48 h, after which the level of cell viability is assayed. The above table shows the dose response of OCM-3 and 92-1. The results are given as percentages of living cells in the samples with Salt I as compared to a 100 % survival of the cells in the samples that are not treated with Salt I. There is a drastic cell loss even at low concentrations of Salt I.

B) IC₅₀ of Salt I on survival of 4 uveal melanoma cell lines (OCM-1, OCM-3, UM 92-1, mel 202) and 2 skin melanoma cell lines (BE and DFB).

melanoma cell line	uveal melanoma cell line				skin cell line	
	OCM-1	OCM-3	UM 92-1	mel 202	BE	DFB
IC ₅₀ µM	0.4	0.15	1.25	0.07	>> 20	>> 20

In the above table, the IC₅₀ doses of Salt I for survival of all 4 uveal melanoma cell lines and of the two skin melanoma cell lines are compared. The IC₅₀ values are 0.07-1.25 µM in the uveal melanoma cells, but >>20 µM in BE and DFB. There is a significant difference in Salt I responsiveness between the cell types, skin melanoma cell lines being no respondent to Salt I.

Example 2: Expression of c-kit in uveal melanoma.

The expression of c-kit is investigated in uveal melanoma samples retrieved from patients by immunohistochemistry and western blot analysis.

A) Expression of c-kit in uveal melanoma

The expression of c-kit in uveal melanomas is investigated by immunohistochemistry on 134 paraffin-embedded surgical specimens of primary uveal melanoma.

Monoclonal antibody: A mouse monoclonal antibody directed to the human c-kit (CD117) was purchased from DAKO (CA, USA).

Immunohistochemistry: Immunostaining is performed using the standard ABC-technique (Vector, Elite Standard Kit. cat. PK-6100). The results of c-kit staining are reported as negative when no staining is present, low when less than 10% of melanoma cells are immunopositive, medium when 10 to 50% are stained and high when more than 50% of the melanoma cells are stained.

Results: Samples are grouped according to staining as: no positive cells, < 10 % positive cells, 10-50% positive cells and > 50 % positive cell as analyzed using an anti-c-kit monoclonal antibody.

	c-kit expression (% of cells positively stained with anti-c-kit MAB)				
	no positive cell	<10%	10% - 50%	> 50%	
number of cases	50	18	18	48	(total) 134

A distinct immunoreactivity confined to the plasma membrane/cytoplasm of tumor cells is found in 64% of the cases (84 of 134). Interestingly, in 48 of 134 (36 %) the majority of tumor cells express c-kit.

B) c-kit expression in frozen samples and skin samples of skin melanoma.

To confirm the results from immunohistochemistry, the expression of c-kit is studied on 8 fresh-frozen samples from primary uveal melanoma and 6 fresh frozen samples from skin melanoma by Western blotting using an antibody specific for c-kit.

Western blotting: Preparation of cell membranes is performed essentially as described elsewhere (Carlberg *et al.* 1996). After centrifugation the material is dissolved in sample buffer for SDS-PAGE. The proteins are transferred overnight onto nitrocellulose membranes.

Incubation with the primary antibody is performed for 1 hour at room temperature, followed by three washes with PBS and incubation with a biotinylated secondary antibody (Amersham) for 1 hour. After a 15-min incubation with streptavidin-labeled horse peroxidase, detection is

performed by enhanced chemiluminiscence. Signal is detected with Hyperfilm-ECL (Amersham).

Results: Six of the uveal melanoma specimens and none of the skin melanoma samples result in a positive signal (data not shown). This result suggests that Salt I might act through the inhibition of c-kit tyrosine phosphorylation to efficiently promote the cell death of uveal melanoma cells.

Example 3: Capsules with 4-[(4-methyl-1-piperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate, beta crystal form

Capsules containing 119.5 mg of Salt I corresponding to 100 mg of Compound I (free base) as active moiety are prepared in the following composition:

Composition:	Salt I	119.5 mg
	Cellulose MK GR	92 mg
	Crospovidone XL	15 mg
	Aerosil 200	2 mg
	Magnesium stearate	1.5 mg

		230 mg

The capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1.

Example 4: Capsules with 4-[(4-methyl-1-piperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate, beta crystal form

Capsules containing 119.5 mg of Salt I corresponding to 100 mg of Compound I (free base) as active moiety are prepared in the following composition:

Composition:	Salt I	119.5 mg
	Avicel	200 mg
	PVPPXL	15 mg
	Aerosil	2 mg
	Magnesium stearate	1.5 mg

		338.0 mg

The capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1.

Example 5: Clinical trials

This is an open label, phase II clinical trial testing SALT I in patients with uveal melanoma for which available evidence suggests an association with kit protein tyrosine kinase.

Patient/Disease population: Patients with uveal melanoma may be eligible to receive Salt I treatment if the following criteria are met relative to their disease:

- the disease has proven to be refractory to standard therapeutic options or no conventional therapies of definitive benefit exist
- tissue samples from the patient express CD117 (c-kit) as tested by immunohistochemical (IHC) assay.

Treatment: Patients with uveal melanoma receive Salt I initially at a dose corresponding to 800 mg per os/day (400 mg bis in diem) of Compound I. Dose levels may be escalated up to 500 mg bis in diem. (1000 mg per os/day) if no significant improvement in the disease occurs after the first eight weeks on therapy. Furthermore, changes in dosing may be based on progression of disease or on relevant laboratory evaluations. Any dose escalation may occur provided the patient may be benefiting from the increased dose of Salt I. Salt I therapy is be continued for as long as the patient is benefiting from treatment with Salt I, in the absence of any safety concerns.


Pharmacodynamic assessments: An overall objective assessment of disease will be performed according to the visit schedules. The 4-week assessment must include all identified disease-associated parameters, including scientific (radiology and laboratory results) and clinical evaluations.

- **FDG-PET scanning:** Based on the putative mechanism of action of the drug, it is possible that a change in the metabolic profile of the tumor will be detectable before any tumor response (as measured by standard radiological methods)-will-occur.-In-order-to-investigate-this-possibility, -- a standard fluorodeoxyglucose (FDG) PET scan is an optional measure of this protocol to be implemented at baseline and after one month of treatment. Earlier FDG-PET scans, i.e. after 7 days of treatment, may also be recommended.

- Dynamic MRI (magnetic resonance imaging): In order to investigate alterations of tumor vascular permeability and blood flow, a standard dynamic MRI procedure with contrast agent injection maybe performed.

Claims:

1. Use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of the following formula



or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of uveal melanoma.

2. The use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide or a pharmaceutically acceptable salt thereof in the treatment of uveal melanoma.

3. The use according to claim 1 or 2 wherein the 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide is in the form of the monomethanesulfonate salt.

4. The use according to claim 1, 2, or 3 wherein the monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide is in the beta crystal form.

5. A method of treating a mammal suffering from uveal melanoma which comprises administering to said human in need of such a treatment a dose, effective against said disease, of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide or a pharmaceutically acceptable salt thereof.

6. The method according to claim 5 wherein the 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide is in the form of the monomethanesulfonate salt.

7. The method according to claim 6 wherein the monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide is in the beta crystal form.
8. The method according to any one of claims 5 to 7 wherein a daily dose of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof corresponding to 100-1000 mg of the free base is administered to a mammal.
9. Use of a c-kit inhibitor or a pharmaceutically acceptable salt thereof for the treatment of uveal melanoma.
10. Use a c-kit inhibitor or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of uveal melanoma.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.